Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
A
|
Abb Ltd
XMUN:ABJA
|
CH |
|
S
|
Salesforce Inc
F:FOO
|
US |
|
B
|
Bper Banca SpA
F:4BE
|
IT |
|
E
|
Endeavour Silver Corp
XMUN:EJD
|
CA |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 386.4 EUR with a low forecast of 202.53 EUR and a high forecast of 504.98 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
386.4
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 386.4 EUR with a low forecast of 202.53 EUR and a high forecast of 504.98 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 8 years is 36%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Net Income over the next 8 years is 41%.
